Results 61 to 70 of about 47,580 (341)

CDR loop interactions can determine heavy and light chain pairing preferences in bispecific antibodies

open access: yesmAbs, 2022
As the current biotherapeutic market is dominated by antibodies, the design of different antibody formats, like bispecific antibodies, is critical to the advancement of the field.
Monica L. Fernández-Quintero   +5 more
doaj   +1 more source

A novel trifunctional IgG-like bispecific antibody to inhibit HIV-1 infection and enhance lysis of HIV by targeting activation of complement [PDF]

open access: yes, 2010
BACKGROUND: The complement system is not only a key component of innate immunity but also provides a first line of defense against invading pathogens, especially for viral pathogens.
Chuanfu Zhang   +14 more
core   +2 more sources

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

open access: yesAdvanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun   +23 more
wiley   +1 more source

Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth

open access: yesNature Communications, 2022
Bispecific antibodies can have advantages compared to antibody cocktails. Here, the authors engineer and characterize two different approaches for generating bispecific SARS-CoV-2 specific antibodies and find that only one design increases antigen ...
Zhiqiang Ku   +24 more
doaj   +1 more source

Identification and characterization of nanobodies targeting the EphA4 receptor [PDF]

open access: yes, 2017
The ephrin receptor A4 (EphA4) is one of the receptors in the ephrin system that plays a pivotal role in a variety of cell-cell interactions, mostly studied during development. In addition, EphA4 has been found to play a role in cancer biology as well as
Chavez-Gutierrez, Lucia   +16 more
core   +2 more sources

Bispecific Antibody-Functionalized Upconversion Nanoprobe [PDF]

open access: yesAnalytical Chemistry, 2018
Upconversion nanoparticles (UCNPs) are new optical probes for biological applications. For specific biomolecular recognition to be realized for diagnosis and imaging, the key lies in developing a stable and easy-to-use bioconjugation method for antibody modification.
Hao He   +7 more
openaire   +3 more sources

Precise Regulation of Membrane Proteins: From Physical Technology to Biomolecular Strategy

open access: yesAdvanced Science, EarlyView.
This review summarizes the emerging strategies for the precise regulation of membrane proteins using physical stimuli and biomolecule‐based tools. These methods provide new insights into cell regulation and offer promising directions for future disease treatment.
Xiu Zhao   +6 more
wiley   +1 more source

CLEC5a-directed bispecific antibody for effective cellular phagocytosis

open access: yesmAbs, 2022
While antibody-dependent cellular phagocytosis mediated by activating Fcγ receptor is a key mechanism underlying many antibody drugs, their full therapeutic activities can be restricted by the inhibitory Fcγ receptor IIB (FcγRIIB).
Vivekananda Kedage   +11 more
doaj   +1 more source

Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing [PDF]

open access: yes, 2017
The anti-FcRH5/CD3 T cell-dependent bispecific antibody (TDB) targets the B cell lineage marker FcRH5 expressed in multiple myeloma (MM) tumor cells. We demonstrate that TDBs trigger T cell receptor activation by inducing target clustering and exclusion ...
Clark, V   +23 more
core   +2 more sources

Bispecific antibodies in cancer immunotherapy [PDF]

open access: yesHuman Vaccines & Immunotherapeutics, 2016
Cancer immunotherapy has recently generated much excitement after the continuing success of the immunomodulating anti-CTLA-4 and anti-PD-1 antibodies against various types of cancers. Aside from these immunomodulating antibodies, bispecific antibodies, chimeric antigen receptor T cells, and other technologies are being actively studied.
Siqi, Chen   +3 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy